FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To observe and evaluate the efficacy and safety of FOLFOX/FOLFIRI± target-directed regimen containing Levofolinic Acid (Zuoyu ®) in first-line treatment of unresectable or metastatic colorectal cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: China Medical University, China

Criteria

Inclusion Criteria:

• Male or female, ≥18 years old;

• Patients with histopathologically confirmed unresectable or metastatic colorectal cancer who have not previously received chemotherapy or targeted therapy for unresectable or metastatic lesions;

• Have at least one measurable lesion according to RECIST 1.1 standards;

• ECOG PS score: 0-2;

• Expected survival greater than 3 months;

• Routine blood routine, liver and kidney function, electrocardiogram and other routine tests were basically normal, no contraindications of chemotherapy;

• The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up visits;

• Researchers believe treatment can benefit.

Exclusion Criteria:

• A proven allergy to the test drug and/or its excipients;

• Pregnant or lactating women;

• Patients judged by the investigator to be unsuitable for inclusion in this study;